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Background
AVX701 is an alphaviral replicon particle vaccine expres-
sing a modified carcinoembryonic antigen gene (CEA
(6D)). We previously reported the preliminary results of a
Phase I/II study of AVX701 in metastatic colorectal cancer
patients (Morse, J Clin Invest. 2010; 120: 3234–3241).
Herein, we now report long-term survival for these
patients and compare their T cell and antibody responses
with the immune responses in a new cohort of stage III
colorectal cancer patients immunized similarly with
AVX701.
Methods
Twenty-eight (28) heavily pretreated patients with predo-
minantly stage IV colorectal cancer were enrolled to 3
dose levels of AVX701 (highest dose 4 × 108 IU i.m. every
3 weeks for 4 immunizations). Subsequently 6 patients
with stage III colorectal cancer who had completed adju-
vant chemotherapy were enrolled to the same regimen.
Peripheral blood from before and after all immunizations
was analyzed for immune responses (IR): anti-CEA anti-
body by ELISA and CEA-specific T cells by ELISPOT.
Results
For the entire metastatic cohort (n=28; 23 deaths), median
OS was 16 months, 95% CI (8, 25). In those treated at the
highest dose (n=19; 14 deaths), there was a trend for a
longer median OS among CEA-specific T cell (ELISPOT)
immune responders vs nonresponders (not reached vs 13
mo, Log rank p=0.10). ELISA data were too sparse to
study OS in the metastatic patients. The difference
between maximum anti-CEA antibody (reciprocal) titer
and baseline was significantly higher in the Stage III
cohort (Normal Scores Test, 2-sided p=0.01) as was the
proportion of patients exhibiting IR by ELISA (100% vs
45.1%; Chi-square p=0.02). In the stage III cohort, mean
ELISPOT values were significantly higher (F-test p =
0.003) and the rate of CEA-specific T cell response by ELI-
SPOT tended to be higher (67% and 30%; Exact Pearson
Chi-square, p=0.16) than in the stage IV cohort.
Conclusions
T cell responses following immunization with AVX701
were associated with a trend for longer survival in
patients with predominantly stage IV colorectal cancer.
The magnitude of antibody response and rate of T cell
response tended to be greater in the stage III than stage
IV patients which may reflect a less immunosuppressive
milieu in patients without measurable disease. We
hypothesize that future combinations with checkpoint
blockade may enhance efficacy in more immunosuppres-
sive environments.
Authors’ details
1Duke University Medical Center, Durham, NC, USA. 2Alphavax, Durham, NC,
USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P444
Cite this article as: Morse et al.: Phase I study of alphaviral vector
(AVX701) in colorectal cancer patients: comparison of immune responses
in stage III and stage IV patients. Journal for ImmunoTherapy of Cancer 2015
3(Suppl 2):P444.
1Duke University Medical Center, Durham, NC, USA
Full list of author information is available at the end of the article
Morse et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P444
http://www.immunotherapyofcancer.org/content/3/S2/P444
© 2015 Morse et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
